Late-stage results Otsuka presented in IgA nephropathy triggered a sell-off in Vera shares. Elsewhere, investors scrutinized ...

A quality improvement strategy can improve electronic health record-based screening for depression and anxiety in people with epilepsy.

The dynamics of the Friedreich's ataxia market are anticipated to change as companies across the globe are thoroughly working toward the deve ...

The agency has provided only limited details about its AI pilot as it advances an “aggressive timeline” for the tool's ...

Biohaven Ltd. will present an investor presentation detailing its ongoing and planned trials for various development programs, including troriluzole, taldefgrobep ...

DelveInsight's Major Depressive Disorder pipeline report depicts a robust space with 75+ active players working to develop ...

PFE stock offers high dividend yields supported by cost optimizations and R&D. Discover its potential amid COVID-19 sales ...

Individuals living near golf courses, as well as those who reside in water service areas that include golf courses, are at ...

The Spinocerebellar Ataxia pipeline is advancing fast as troriluzole nears FDA nod and rivals race with gene and stem cell therapies to seize market edge. Disease modification in spinocerebellar ...

We recently published a list of Jim Cramer’s Thoughts on These 10 Stocks. In this article, we are going to take a look at ...